Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Absci Corp (ABSI)

Absci Corp (ABSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Mar 6, 3:05PM CST

VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 2.51 (+5.46%)
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer GlobeNewswire - Tue Mar 3, 7:00AM CST

Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue...

ABSI : 2.51 (+5.46%)
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 GlobeNewswire - Tue Feb 24, 7:00AM CST

VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 2.51 (+5.46%)
Absci to Participate in Upcoming Investor Conferences GlobeNewswire - Tue Feb 17, 7:00AM CST

VANCOUVER, Wash. and NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today...

ABSI : 2.51 (+5.46%)
Medical Breakthroughs: 5 AI Innovators Redefining What's Possible BayStreet.ca - Thu Dec 18, 2025

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – The healthcare AI market reached $21.66 billion in 2025 and analysts now project growth to $110.61...

CBLL : 18.28 (+2.52%)
ONMD : 0.6900 (+1.47%)
VPT.VN : 0.115 (unch)
LNAI : 0.2200 (-5.25%)
ABSI : 2.51 (+5.46%)
VPTDF : 0.0855 (+3.89%)
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Tue Dec 16, 2025

VANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today...

ABSI : 2.51 (+5.46%)
Financial Pressure Turns Healthcare AI From Pilots Into Profits BayStreet.ca - Fri Dec 12, 2025

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – Healthcare providers shortened buying cycles from eight months to under seven as financial pressures...

VPT.VN : 0.115 (unch)
CCLD : 2.73 (-0.36%)
ABSI : 2.51 (+5.46%)
LNAI : 0.2200 (-5.25%)
CAI : 19.00 (+2.21%)
VPTDF : 0.0855 (+3.89%)
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion BayStreet.ca - Fri Dec 12, 2025

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in November...

ONCY : 1.0600 (unch)
SANA : 3.33 (+5.71%)
ABSI : 2.51 (+5.46%)
RXRX : 3.51 (+1.45%)
TEM : 52.32 (+0.11%)
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization GlobeNewswire - Thu Dec 11, 2025

Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth  ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular...

ABSI : 2.51 (+5.46%)
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research GlobeNewswire - Wed Dec 10, 2025

Partnership aims to destigmatize androgenetic alopecia and highlight the need for new therapeutic options that address the root cause of disease Donovan to share his personal journey at Absci’s...

ABSI : 2.51 (+5.46%)

Barchart Exclusives

Dear Vertiv Stock Fans, Mark Your Calendars for March 23 Barchart - 44 minutes ago
Vertiv shares rally ahead of inclusion in the S&P 500 index on Mar. 23. Oppenheimer explains why VRT stock remains worth owning in 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot